David Uehling

4.6k total citations · 1 hit paper
46 papers, 3.2k citations indexed

About

David Uehling is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, David Uehling has authored 46 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Molecular Biology, 15 papers in Organic Chemistry and 13 papers in Oncology. Recurrent topics in David Uehling's work include Receptor Mechanisms and Signaling (6 papers), Melanoma and MAPK Pathways (5 papers) and Asymmetric Synthesis and Catalysis (5 papers). David Uehling is often cited by papers focused on Receptor Mechanisms and Signaling (6 papers), Melanoma and MAPK Pathways (5 papers) and Asymmetric Synthesis and Catalysis (5 papers). David Uehling collaborates with scholars based in Canada, United States and Italy. David Uehling's co-authors include Andrzej Gałat, Stuart L. Schreiber, Matthew W. Harding, Clayton H. Heathcock, Stuart L. Schreiber, Rima Al‐awar, Tarek Sammakia, John A. Ragan, Masashi Nakatsuka and David B. Smith and has published in prestigious journals such as Nature, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

David Uehling

46 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A receptor for the immuno-suppressant FK506 is a cis–trans peptidyl-prolyl isomerase

1989 1.2k citations Matthew W. Harding, Andrzej Gałat et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Uehling Canada	27	2.3k	800	756	411	207	46	3.2k
Swee Y. Sharp United Kingdom	25	2.0k 0.9×	750 0.9×	417 0.6×	287 0.7×	303 1.5×	45	2.8k
Stephen K. Tahir United States	22	2.4k 1.0×	980 1.2×	331 0.4×	391 1.0×	245 1.2×	35	3.3k
Luciana Marinelli Italy	43	3.1k 1.3×	912 1.1×	1.2k 1.5×	407 1.0×	292 1.4×	164	5.1k
Akira Asai Japan	33	1.8k 0.8×	649 0.8×	938 1.2×	275 0.7×	337 1.6×	132	3.0k
A. Chaikuad Germany	37	2.9k 1.3×	784 1.0×	760 1.0×	296 0.7×	349 1.7×	123	4.4k
K. Huber United Kingdom	26	1.9k 0.8×	665 0.8×	518 0.7×	248 0.6×	262 1.3×	60	3.0k
Michelle A. Blaskovich United States	27	1.9k 0.8×	1.4k 1.7×	454 0.6×	545 1.3×	185 0.9×	44	3.3k
Paul E. Brennan United Kingdom	38	3.6k 1.6×	609 0.8×	904 1.2×	223 0.5×	96 0.5×	114	4.9k
Steven W. Elmore United States	24	3.2k 1.4×	1.2k 1.5×	716 0.9×	623 1.5×	159 0.8×	37	4.8k
Joerg Kallen Switzerland	31	1.9k 0.8×	738 0.9×	329 0.4×	771 1.9×	322 1.6×	58	3.6k

Countries citing papers authored by David Uehling

Since Specialization

Citations

This map shows the geographic impact of David Uehling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Uehling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Uehling more than expected).

Fields of papers citing papers by David Uehling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Uehling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Uehling. The network helps show where David Uehling may publish in the future.

Co-authorship network of co-authors of David Uehling

This figure shows the co-authorship network connecting the top 25 collaborators of David Uehling. A scholar is included among the top collaborators of David Uehling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Uehling. David Uehling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rudolph, Joachim, et al.. (2023). Which Small Molecule? Selecting Chemical Probes for Use in Cancer Research and Target Validation. Cancer Discovery. 13(10). 2150–2165. 5 indexed citations

Adile, Ashley, David Bakhshinyan, Yujin Suk, et al.. (2023). An effective kinase inhibition strategy for metastatic recurrent childhood medulloblastoma. Journal of Neuro-Oncology. 163(3). 635–645. 2 indexed citations

Ganguly, Amlan, Tezz Quon, Laura Jenkins, et al.. (2023). G protein–receptor kinases 5/6 are the key regulators of G protein–coupled receptor 35–arrestin interactions. Journal of Biological Chemistry. 299(10). 105218–105218. 5 indexed citations

Steyaert, Wouter, Paul Coucke, Joris Delanghe, et al.. (2022). G protein–coupled receptor kinase 6 (GRK6) regulates insulin processing and secretion via effects on proinsulin conversion to insulin. Journal of Biological Chemistry. 298(10). 102421–102421. 5 indexed citations

Uehling, David, Babu Joseph, Kim Chan Chung, et al.. (2021). Design, Synthesis, and Characterization of 4-Aminoquinazolines as Potent Inhibitors of the G Protein-Coupled Receptor Kinase 6 (GRK6) for the Treatment of Multiple Myeloma. Journal of Medicinal Chemistry. 64(15). 11129–11147. 16 indexed citations

Lun, Xueqing, J. Connor Wells, Natalie Grinshtein, et al.. (2016). Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma. Clinical Cancer Research. 22(15). 3860–3875. 169 indexed citations

Hammoud, Lamis, Jessica R. Adams, Amanda J. Loch, et al.. (2016). Identification of RSK and TTK as Modulators of Blood Vessel Morphogenesis Using an Embryonic Stem Cell-Based Vascular Differentiation Assay. Stem Cell Reports. 7(4). 787–801. 14 indexed citations

Babichev, Yael, Alessandro Datti, David Uehling, et al.. (2016). PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma. Journal of Translational Medicine. 14(1). 67–67. 42 indexed citations

Deng, Tao, Jeff C. Liu, Philip E.D. Chung, et al.. (2014). shRNA Kinome Screen Identifies TBK1 as a Therapeutic Target for HER2+ Breast Cancer. Cancer Research. 74(7). 2119–2130. 29 indexed citations

10.

Liu, Jeff C., Véronique Voisin, Dong‐Yu Wang, et al.. (2014). Combined deletion of P ten and p53 in mammary epithelium accelerates triple‐negative breast cancer with dependency on e EF 2 K. EMBO Molecular Medicine. 6(12). 1542–1560. 84 indexed citations

11.

King, Alastair J., Marc R. Arnone, Maureen R. Bleam, et al.. (2013). Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions. PLoS ONE. 8(7). e67583–e67583. 163 indexed citations

12.

Cojocari, Dan, Ravi N. Vellanki, Brandon Sit, et al.. (2013). New small molecule inhibitors of UPR activation demonstrate that PERK, but not IRE1α signaling is essential for promoting adaptation and survival to hypoxia. Radiotherapy and Oncology. 108(3). 541–547. 35 indexed citations

13.

Enwere, Emeka K., Methvin Isaac, David Uehling, et al.. (2012). TWEAK and cIAP1 Regulate Myoblast Fusion Through the Noncanonical NF-κB Signaling Pathway. Science Signaling. 5(246). ra75–ra75. 67 indexed citations

14.

Grinshtein, Natalie, Alessandro Datti, David Uehling, et al.. (2011). Small Molecule Kinase Inhibitor Screen Identifies Polo-Like Kinase 1 as a Target for Neuroblastoma Tumor-Initiating Cells. Cancer Research. 71(4). 1385–1395. 76 indexed citations

15.

Stellwagen, John, George M. Adjabeng, Marc R. Arnone, et al.. (2011). Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup. Bioorganic & Medicinal Chemistry Letters. 21(15). 4436–4440. 22 indexed citations

16.

Mahoney, Douglas J., Charles Lefebvre, J Brun, et al.. (2011). Virus-Tumor Interactome Screen Reveals ER Stress Response Can Reprogram Resistant Cancers for Oncolytic Virus-Triggered Caspase-2 Cell Death. Cancer Cell. 20(4). 443–456. 77 indexed citations

17.

Waterson, Alex G., Kimberly G. Petrov, Keith R. Hornberger, et al.. (2009). Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 19(5). 1332–1336. 33 indexed citations

18.

Uehling, David, et al.. (1995). Synthesis, Topoisomerase I Inhibitory Activity, and in Vivo Evaluation of 11-Azacamptothecin Analogs. Journal of Medicinal Chemistry. 38(7). 1106–1118. 46 indexed citations

19.

Luzzio, Michael J., Jeffrey M. Besterman, David L. Emerson, et al.. (1995). Synthesis and Antitumor Activity of Novel Water Soluble Derivatives of Camptothecin as Specific Inhibitors of Topoisomerase I. Journal of Medicinal Chemistry. 38(3). 395–401. 122 indexed citations

20.

Harding, Matthew W., Andrzej Gałat, David Uehling, & Stuart L. Schreiber. (1989). A receptor for the immuno-suppressant FK506 is a cis–trans peptidyl-prolyl isomerase. Nature. 341(6244). 758–760. 1154 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact